GU Cancers Symposium 2014 - 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ALSYMPCA study - Poster

SAN FRANCISCO, CA USA ( - Presented by S. Nilsson,1 N. Vogelzang,2 O. Sartor,3 D. Bottomley,4 R. Coleman,5 I. Skjorestad,6 M. Wahba,7 and C. Parker8 at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Nilsson ASCOGU 2014 thumb

1Karolinska University Hospital, Stockholm, Sweden; 2Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; 3Tulane Cancer Center, New Orleans, LA, USA; 4St. James Hospital, Leeds, UK; 5Weston Park Hospital, Sheffield, UK; 6Algeta ASA, Oslo, Norway; 7Bayer HealthCare, Whippany, NJ, USA; 8The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK 

Click HERE to read an exclusive report by a UroToday medical writer

Click HERE to listen to an exclusive interview with one of the authors of this study

View Full 2014 GU Cancers Symposium Coverage 




Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.